These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30037860)

  • 1. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
    Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS
    BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
    J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
    Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
    Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
    Zeidan AM; Klink AJ; McGuire M; Feinberg B
    Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL; Cosler LE; Ferro SA; Lyman GH
    J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of myelodysplastic syndromes: 2008 update.
    Scott BL; Estey E
    Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
    Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
    Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
    Killick SB; Ingram W; Culligan D; Enright H; Kell J; Payne EM; Krishnamurthy P; Kulasekararaj A; Raghavan M; Stanworth SJ; Green S; Mufti G; Quek L; Cargo C; Jones GL; Mills J; Sternberg A; Wiseman DH; Bowen D
    Br J Haematol; 2021 Jul; 194(2):267-281. PubMed ID: 34180045
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of myelodysplastic syndromes in the geriatric patient.
    Ritchie EK; Lachs MS
    Curr Hematol Malig Rep; 2009 Jan; 4(1):3-9. PubMed ID: 20425432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.
    Prebet T; Toma A; Cluzeau T; Sekeres MA; Vey N; Park S; Al Ali N; Sugrue MM; Komrokji R; Fenaux P; Gore SD
    Oncotarget; 2017 Jun; 8(23):37866-37874. PubMed ID: 28184031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does early diagnosis and treatment of myelodysplastic syndromes make a difference?
    Steensma DP
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101099. PubMed ID: 31779983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
    Messingerová L; Jonášová A; Barančik M; Poleková L; Šereš M; Gibalová L; Breier A; Sulová Z
    Gen Physiol Biophys; 2015 Oct; 34(4):399-406. PubMed ID: 26001289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.